Skip to main content

Table 3 LncRNA expression level and clinical feature analysis of 22 cases of LADC from Xiangya hospital

From: Identification of LINC02310 as an enhancer in lung adenocarcinoma and investigation of its regulatory network via comprehensive analyses

Clinical features lnc-YARS2-5 lnc-NPR3-2 LINC02310
Low High p1 p2 Low High p1 p2 Low High p1 p2
Age             
  < 55   1 5 0.615 0.457 3 5  > 0.99 0.636 2 6  > 0.99  > 0.99
  ≥ 55   4 8 3 8 3 9
Gender             
 Male   4 8 0.615 0.457 6 7 0.109 0.044 5 9 0.260 0.091
 Female   1 5 0 6 0 6
T-stage             
 T1   5 4 0.029 0.009 1 8 0.141 0.069 0 10 0.033 0.010
 T2/T3/T4   0 9 5 5 5 5
N-stage             
 N0   5 7 0.114 0.063 1 10 0.041 0.013 2 11 0.290 0.176
 N1/N2/N3   0 6 5 3 3 4
TNM-stage             
 I   4 4 0.118 0.060 1 7 0.177 0.127 0 9 0.038 0.020
 II/III/IV   1 9 5 6 5 6
Differentiation             
 Low   1 5 0.542 0.395 2 4  > 0.99 0.937 2 4 0.346 0.310
 Mid-low   1 2 1 2 1 2
 Mid   1 3 2 2 0 4
 Mid-high   1 0 1 1 2 1
  1. ‘Low’ and ‘high’ denote the cases where the DElncRNAs were low expressed and high expressed, respectively. p1 and p2 are the p-values obtained via Fisher’s accurate test and Pearson’s chi-squared test, respectively